Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUMFDU)

Drug Name

ARV-1801 Drug Info

Synonyms

ACG-701

Indication

Disease Entry	ICD 11	Status	REF
Melioidosis	1C42	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein synthesis (hPRO synth)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Contezolid acefosamil	DMMOHUA	Acute bacterial skin infection	1C41	Phase 2	[3]
Contezolid	DMZ0F65	MRSA infection	1D01.0Y	Phase 2	[3]
Zilascorb (2H)	DM3IRES	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein synthesis (hPRO synth)	TTLIZBJ	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05105035) A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized Patients. U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Anticancer Drugs. 1997 Mar;8(3):296-303.